221 CRESCENT STREET, WALTHAM, MA
Market cap: $2.4B (2/09/2026)
Price: $30.06
Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Viridian Therapeutics Enters Underwriting Agreement for $251.35M Offering
Company Expects Approximately $490.9 Million in Cash as of September 30, 2025
Viridian Therapeutics Enters $300 Million Purchase and Sale Agreement
Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
Viridian Therapeutics Partners with Kissei for Veligrotug and VRDN-003 in Japan, $70M Upfront, $315M Milestones
Changes in Board, Management or Compensation, Shareholder votes
Investor Presentation
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
S-8 POS
Correspondence
Submission Upload